Neubase_Logo_RGB_Black.png
NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference
September 28, 2021 16:05 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using...
Neubase_Logo_RGB_Black.png
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 
September 15, 2021 16:05 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer
September 14, 2021 08:00 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference
September 01, 2021 16:05 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
August 12, 2021 16:01 ET | NeuBase Therapeutics, Inc.
Further demonstrated broad potential of novel genetic medicine platform with in vivo data in three diseases driven by different genetic mechanisms of diseasePresented preclinical data showing...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth
June 08, 2021 12:30 ET | NeuBase Therapeutics, Inc.
Data presented today at NeuBase’s R&D Day show functional rescue of myotonic dystrophy type 1 (DM1) phenotype in vivo after subcutaneous dosing; positions program to enter the clinic in CY...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th
June 02, 2021 09:00 ET | NeuBase Therapeutics, Inc.
Company to present new preclinical data in myotonic dystrophy type 1 to support a path to enter the clinic in 2022, as well as provide updates on the Huntington’s disease program and unveil a new...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
May 25, 2021 08:00 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, May 25, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
May 20, 2021 08:00 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021
May 14, 2021 12:31 ET | NeuBase Therapeutics, Inc.
RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19 Oppenheimer Rare & Orphan Disease Summit presentation on May 21 PITTSBURGH, May 14, 2021 ...